[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627493":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":40,"responsibleParty":59,"collaborators":62,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":26,"eligibilityCriteria":71,"healthyVolunteers":72,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":26,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":91,"whyStopped":26,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Yale University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Psychedelic group","ACTIVE_COMPARATOR","An imperceptible dose of psilocybin in capsules will be administered to subjects three times weekly for four weeks. Assessments will be conducted once weekly. After 30 days of a steady dose of psilocybin, subjects will be re-assessed with baseline measures.",[13],"Drug: Psliocybin",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo group","PLACEBO_COMPARATOR","An dose of placebo in capsules, identical to the active, will be administered to subjects three times weekly for four weeks. Assessments will be conducted once weekly. After 30 days of a steady dose of psilocybin, subjects will be re-assessed with baseline measures.",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Psliocybin","2.0mg powdered psilocybin derived from Psilocybe cubensis mushrooms, in capsules, provided three times weekly for four weeks",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","0mg matching capsules, provided three times weekly for four weeks",[15],[32],{"name":33,"affiliation":5,"role":34},"Godfrey Pearlson, MD","PRINCIPAL_INVESTIGATOR",[36],{"name":33,"role":37,"phone":38,"phoneExt":26,"email":39},"CONTACT","860-545-7757","godfrey.pearlson@hhchealth.org",[41],{"facility":42,"status":26,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Olin Neuropsychiatry Research Center","Hartford","Connecticut","06106","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-72.68509,41.76371,{"lat":52,"lon":51},[55],{"name":56,"role":37,"phone":57,"phoneExt":26,"email":58},"Diana King","860-545-7563","diana.king@hhchealth.org",{"type":34,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Godfrey Pearlson","Professor of Psychiatry and Neuroscience, Founding Director Olin Neuropsychiatry Research Center",[63],{"name":64,"class":6},"Hartford HealthCare","100627493","early-phase-1-psilocybin-microdosing-on-cognition-mood-and-quality-of-life-100627493",false,"NCT07449351","Psilocybin Microdosing on Cognition, Mood and Quality of Life","Effects of Psilocybin Microdosing on Cognition, Mood and Quality of Life: A Pilot Study","Inclusion Criteria:\n\n* No history of psychedelic use\n* Able to read, speak, and understand English\n* Able and willing to provide written informed consent, and willing to commit to study protocol\n* Women of childbearing potential must be on a highly effective birth control method\n\nExclusion Criteria:\n\n* Positive screen for recreational drugs or alcohol on test day will result in rescheduling the appointment\n* Current mood, developmental, or psychotic disorders (e.g., schizophrenia, affective disorders) per DSM-V\n* Current or past alcohol or substance use disorder per DSM-V\n* IQ \\\u003C70 on the Weschler Abbreviated Scale of Intelligence\n* Serious medical, neuro-ophthalmological, or neurological illness (e.g., cancer, seizure disorders, encephalopathy)\n* Current pregnancy, breastfeeding, or ineffective birth control methods\n* History of head trauma with loss of consciousness lasting \\>30 minutes or concussion in last 30 days\n* Any medical\u002Fneurological condition that could compromise neurocognitive performance (e.g., epilepsy, multiple sclerosis, fetal alcohol syndrome)\n* Anyone deemed unsafe to study personnel for any reason; e.g., suicidal ideation\n* Focal brain lesion seen on structural MRI\n* MRI contraindications (e.g., implanted metallic object, severe claustrophobia)",true,"ALL","21 Years","40 Years",{"count":77,"type":78},20,"ESTIMATED","INTERVENTIONAL",[81],"EARLY_PHASE1","This study is being conducted to evaluate how of 30 days of intermittently microdosed psilocybin affects mood, cognition, subjective well-being and structural\u002Ffunctional MRI results compared to a placebo. Investigators hypothesize that compared to placebo, 30 days of intermittently microdosed psilocybin will produce observable changes in mood, cognition, subjective well-being and MRI, in the absence of psychedelic experiences.",[84],"Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI",[86,87,88,89,90],"Psychedelics","Psilocybin","MRI","fMRI","Microdosing","NOT_YET_RECRUITING","2026-06-19",{"date":94,"type":95},"2026-06-23","ACTUAL",{"date":97,"type":78},"2026-08-10",{"date":99,"type":78},"2028-04-01",{"name":5,"class":6},1]